Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Earnings Beats
  • Earnings Misses
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Macro Economic Events
  • Management
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Termination
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week
Browsing Category

News

Group By Ticker
Sort By
Newest | Oldest
Read More
1 minute read
  • Analyst Ratings
  • News
  • Price Target

Raymond James Maintains Strong Buy on Polaris, Raises Price Target to $130

By Benzinga Newsdesk
Today, 8:17 AM
Raymond James analyst Joseph Altobello maintains Polaris (NYSE:PII) with a Strong Buy and raises the price target from $123 to $130.

PII

Read More
1 minute read
  • Analyst Ratings
  • Initiation
  • News
  • Price Target

Mizuho Initiates Coverage On General Mills with Neutral Rating, Announces Price Target of $75

By Benzinga Newsdesk
Today, 8:15 AM
Mizuho analyst John Baumgartner initiates coverage on General Mills (NYSE:GIS) with a Neutral rating and announces Price Target of $75.

GIS

Read More
1 minute read
  • Biotech
  • General
  • Health Care
  • News

Plus Therapeutics Has Completed Of Enrollment In Cohort 2 Of The Respect-LM Phase 1/2a Dose Escalation Trial Of Rhenium (186Re) Obisbemeda For Leptomeningeal Metastases

By Benzinga Newsdesk
Today, 8:13 AM
The company said the next steps, following the Data and Safety Monitoring Board review anticipated next month, will be completing enrollment in Phase 1/Part A, followed by a meeting with the FDA to consider dose

PSTV

Read More
1 minute read
  • Analyst Ratings
  • News
  • Price Target

Mizuho Maintains Buy on Advanced Micro Devices, Lowers Price Target to $90

By Benzinga Newsdesk
Today, 8:11 AM
Mizuho analyst Vijay Rakesh maintains Advanced Micro Devices (NASDAQ:AMD) with a Buy and lowers the price target from $95 to $90.

AMD

Read More
1 minute read
  • News
  • Tech

Auddia Has Created A Proprietary Audio Content Hosting And Streaming System To Support The Unique And Exclusive Demands Offered In Its Flagship Mobile App, Faidr

By Benzinga Newsdesk
Today, 8:09 AM
The company launched faidrRadio, currently only available in its iOS product, which includes Music Casts and Music Stations on January 24. Music Casts will be added to its Android app later in Q1.

AUUD

Read More
1 minute read
  • Earnings
  • News

Spire Q1 EPS $1.55 Beats $1.05 Estimate, Sales $814.00M Beat $559.18M Estimate

By Benzinga Newsdesk
Today, 8:06 AM
Spire (NYSE:SR) reported quarterly earnings of $1.55 per share which beat the analyst consensus estimate of $1.05 by 47.62 percent. This is a 35.96 percent increase over earnings of $1.14 per share from the same period

SR

Read More
1 minute read
  • FDA
  • News

XORTX Announced Submission of Orphan Drug Designation Request for XRx-008 Program to Treat Autosomal Dominant Kidney Disease

By Charles Gross
Today, 8:05 AM
- XORTX Therapeutics Inc.

TSXV:XRTX

Read More
1 minute read
  • Guidance
  • News

Altria FY23 Adj. EPS Outlook $4.98 – $5.13 Vs. $5.00 Est

By Benzinga Newsdesk
Today, 8:03 AM
We expect our 2023 full-year adjusted diluted EPS to be in a range of $4.98 to $5.13, representing a growth rate of 3% to 6% from an adjusted diluted EPS base of $4.84 in 2022. While the 2023 full-year adjusted diluted

MO

Read More
1 minute read
  • Earnings
  • News

Johnson Controls Intl Q1 Adj EPS $0.67, Inline, Sales $6.07B Miss $6.25B Estimate

By Benzinga Newsdesk
Today, 7:58 AM
Johnson Controls Intl (NYSE:JCI) reported quarterly earnings of $0.67 per share which met the analyst consensus estimate. This is a 24.07 percent increase over earnings of $0.54 per share from the same period last year.

JCI

Read More
1 minute read
  • Analyst Ratings
  • News
  • Price Target

Credit Suisse Maintains Outperform on TransDigm Gr, Raises Price Target to $765

By Benzinga Newsdesk
Today, 7:56 AM
Credit Suisse analyst Scott Deuschle maintains TransDigm Gr (NYSE:TDG) with a Outperform and raises the price target from $735 to $765.

TDG

Posts navigation

1 2 … 14,998 Next
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service